Samsung Bioepis and its European partner Biogen have been dealt a legal blow in Germany after a higher court ruled that ...

D&D Pharmatech said Monday that its GLP-1/glucagon dual agonist DD01 met the primary endpoint in a U.S. phase 2 study in ...

A 16-month-long government-doctor conflict is unable to find a way out. The hope that a change in political power will soon ...

Just because you can't hear doesn't mean you can't sing.Big Ocean, the world's first deaf idol group, is proof of this.

Patients with urothelial carcinoma are increasingly abandoning treatment. New drugs are being developed, but health insurance ...

Takeda Korea has launched Fruzaqla (fruquintinib), a once-daily oral treatment for metastatic colorectal cancer (mCRC), ...

A mobile game-based digital therapy has been shown to help improve social skills in adolescents with autism spectrum disorder ...

Celltrion has picked up additional approvals from the FDA and Health Canada for its biosimilar to Janssen’s Stelara, Steqeyma ...

Yuhan Corp. is making an early case for its allergy biologic YH35324 in chronic spontaneous urticaria (CSU), the medical term ...

Samsung Biologics has officially launched a new organoid-based drug screening platform, “Samsung Organoids,” as part of its ...

“Korean patients in the ASCENT-04 trial were happy to be in the trial, even if assigned to the placebo arm.”A breast cancer specialist I met last week at the American Society of Clinical Oncology Annu ...

A research team at Seoul National University Bundang Hospital (SNUBH) recently published a study demonstrating that the ...